Q-omics provides the consensus-scored CFL1P8 profile across patient tissues and cancer cell-line models. CFL1P8 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, CFL1P8 is differentially expressed in 3, with the highest sampling consensus in STAD. Additionally, CFL1P8 RNA expression shows 6,257 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCS, and STAD as cancer lineages where CFL1P8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFL1P8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFL1P8 survival associations across molecular data types. CFL1P8 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFL1P8 RNA expression–survival associations across cancer types. High CFL1P8 expression shows unfavorable associations in STAD, COAD and PCPG, but favorable associations in UCS, HNSC and ESCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify UCS as the clearest survival context for CFL1P8 RNA expression.
This table summarizes CFL1P8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CFL1P8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFL1P8 shows higher tumor expression in STAD, KIRC and LUAD. The STAD box plot shows higher CFL1P8 RNA expression in tumor versus normal tissue (log2 FC = +0.050, t-test p = .032).
This table shows molecular features associated with CFL1P8 in patient tissues and cancer cell lines. In patient samples, CFL1P8 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
